Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by Ticklel1ston Apr 03, 2020 12:41am
210 Views
Post# 30874643

The last NR relevance to anti virus

The last NR relevance to anti virusFrom the Sironavirus website..Sirona Biochem has expertise in the development of carbohydrate-based molecules.  Essential to life, carbohydrates, or sugar molecules, have broad potential for ground-breaking pharmaceutical and cosmetic development as they play a critical role in most of the major diseases. Carbohydrates are implied in a wide range of biological functions, cell/cell communication, immunity and cancer development. It is thus their central role in the communication between cells and their ability to interact with proteins, hormones, viruses, toxins or bacteria which make carbohydrate-based molecules major candidates for the development of new curative treatments for cancer, viral infections, inflammation and many other areas.

Despite this immense potential, a major limitation of carbohydrate molecules is their lack of stability.  When coming into contact with omnipresent enzymes, for example, carbohydrate-based molecules can easily break down or become toxic, making them difficult to produce as pharmaceutical products.

Sirona Biochem’s French subsidiary, TFChem, has developed a proprietary chemistry technique that maintains the integrity of carbohydrate-based molecules even after enzyme exposure.  Through years of award-winning research by our synthetic chemists, we have learned how to strengthen the bond of a carbohydrate molecule by strategically placing fluorine atoms within the molecule.  This technique has yielded several compounds showing promise for the development of different kinds of therapeuticscosmetic agents and as biological ingredients for laboratory use.

Our research so far has demonstrated that by applying our chemistry technique we can enhance the stability and bioavailability of carbohydrate-based molecules. Since the modulations induced by the introduction of fluorine atoms onto a molecule has a major influence on its behavior within the biological medium, it’s not surprising that fluorine is now present in 20 to 30 % of the drugs of the market. However, our proprietary fluorine-based chemistry platform not only gives our company the chance to develop new robust compounds, but also allows us to improve previously-developed compounds by other companies.  Those compounds may have otherwise been put on hold because of the inherent challenges of carbohydrate-based chemistry.


Bullboard Posts